Serum steroids in relation to prostate cancer risk in a case-control study (Greece)

Cancer Causes and Control

Volumn 8, Issue 4, 1997, Pages 632-636

  Signorello, Lisa B ^a   Tzonou, Anastasia ^b   Mantzoros, Christos S ^a,c   Lipworth, Loren ^a   Lagiou, Pagona ^a,d   Hsieh, Chung Cheng ^e   Stampfer, Meir ^a   Trichopoulos, Dimitrios ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Dihydrotestosterone; Estradiol; Greece; Men; Prostate cancer; Sex hormone binding globulin; Testosterone

Indexed keywords

ESTRADIOL; SEX HORMONE BINDING GLOBULIN; STEROID; TESTOSTERONE;

ADULT; AGED; ANALYTIC METHOD; BLOOD SAMPLING; CANCER REGRESSION; CANCER RISK; CASE CONTROL STUDY; DRUG BLOOD LEVEL; GREECE; HISTOLOGY; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; REVIEW;

AGED; CASE-CONTROL STUDIES; DIHYDROTESTOSTERONE; ESTRADIOL; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PROSTATIC NEOPLASMS; RESIDENCE CHARACTERISTICS; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; URBAN HEALTH;

EID: 0030746579     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018454632045     Document Type: Review

References (21)

1. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. JNCI 1995; 87: 190-7.
2. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. JNCI 1996; 88: 291-6.
3. Henderson BE, Ross BK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42: 3232-9.
4. Hsing AW. Hormones and prostate cancer: Where do we go from here? JNCI 1996; 88: 1093-5.
5. Nomura AM, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991; 13: 200-27.
6. Andersson SO, Adami HO, Bergstrom R, Wide L. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population based case-control study. Br J Cancer 1993; 68: 97-102.
7. Meikle AW, Smith JA, Stringham JD. Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 1987; 10: 25-31.
8. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomark Prev 1993; 2: 27-32.
9. Noniura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988; 48: 3515-7.
10. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990; 50: 169-73.
11. Gann PH, Hennekens CH, MaJ, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. JNCI 1996; 88: 1118-26.
12. Nomura A, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomark Prev 1996; 5: 621-5.
13. Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume I. The Analysis of Case-control Studies. Lyon, France: International Agency for Research on Cancer, 1980; IARC Sci. Pub. No. 32.
14. Stata Corporation. STATA. Release 5.0. College Station, TX (USA): Stata Corporation, 1997; Stata Statistical Software.
15. Ghanadian R, Puah CM, O'Donoghue EPN. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 1979; 39: 696-9.
16. Ahluwalia B, Jackson MA, Jones GW, Williams AO, Rao MS, Rajguru S. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer 1981; 48: 2267-73.
17. Zumoff B, Levin J, Strain GW, et al. Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a 'two-disease' theory. Prostate 1982; 3: 579-88.
18. MacMahon B, Cole P, Brown JB, Paffenbarger R, Trichopoulos D, Yen S. Urine estrogens, frequency of ovulation, and breast cancer risk: case-control study in premenopausal women. JNCI 1983; 70: 247-50.
19. Montie JE, Pienta K. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 1994; 43: 892-8.
20. Geller J. Approach to chemoprevention of prostate cancer. J Clin Endocrinol Metab 1995; 80: 717-9.
21. Lee C, Sutkowski DM, Sensibar JA, et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995; 136: 796-803.